These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 29675797)

  • 41. Real-world impact of adding a glucagon-like peptide-1 receptor agonist compared with basal insulin on metabolic targets in adults living with type 2 diabetes and chronic kidney disease already treated with a sodium-glucose co-transporter-2 inhibitor: The Impact GLP-1 CKD study.
    Chu L; Bradley RM; Auerbach P; Abitbol A
    Diabetes Obes Metab; 2024 Oct; 26(10):4674-4683. PubMed ID: 39113258
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Addition of Basal Insulin to Oral Antidiabetic Agents in Patients with Inadequately Controlled Type 2 Diabetes Leads to Improved HbA1c Levels: Metabolic Control, Frequency of Hypoglycemia, and Insulin Titration Analysis as Results of a Prospective Observational Study (BALI Study).
    Brož J; Janíčková Ždárská D; Štěpánová R; Kvapil M
    Diabetes Ther; 2019 Apr; 10(2):663-672. PubMed ID: 30788806
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Treatment intensification following glucagon-like peptide-1 receptor agonist in type 2 diabetes: Comparative effectiveness analyses between free vs. fixed combination of GLP-1 RA and basal insulin. RESTORE-G real-world study.
    Candido R; Nicolucci A; Larosa M; Rossi MC; Napoli R;
    Nutr Metab Cardiovasc Dis; 2024 Aug; 34(8):1846-1853. PubMed ID: 38693036
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Glycemic Control and Weight Outcomes for Exenatide Once Weekly Versus Liraglutide in Patients with Type 2 Diabetes: A 1-Year Retrospective Cohort Analysis.
    McAdam-Marx C; Nguyen H; Schauerhamer MB; Singhal M; Unni S; Ye X; Cobden D
    Clin Ther; 2016 Dec; 38(12):2642-2651. PubMed ID: 27889301
    [TBL] [Abstract][Full Text] [Related]  

  • 45. "Act on Threes" Paradigm for Treatment Intensification of Type 2 Diabetes in Managed Care: Results of a Randomized Controlled Study with an Educational Intervention Targeting Improved Glycemic Control.
    Bieszk N; Reynolds SL; Wei W; Davis C; Kamble P; Uribe C
    J Manag Care Spec Pharm; 2016 Sep; 22(9):1028-38. PubMed ID: 27579824
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical and Economic Outcomes Associated With the Timing of Initiation of Basal Insulin in Patients With Type 2 Diabetes Mellitus Previously Treated With Oral Antidiabetes Drugs.
    Levin P; Zhou S; Durden E; Farr AM; Gill J; Wei W
    Clin Ther; 2016 Jan; 38(1):110-21. PubMed ID: 26681210
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Longitudinal changes in glycated haemoglobin following treatment intensification after inadequate response to two oral antidiabetic agents in patients with type 2 diabetes.
    Kim K; Unni S; Brixner DI; Thomas SM; Olsen CJ; Sterling KL; Mitchell M; McAdam-Marx C
    Diabetes Obes Metab; 2019 Jul; 21(7):1725-1733. PubMed ID: 30848039
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Switching to a fixed-ratio combination of insulin degludec/liraglutide (IDegLira) is associated with improved glycaemic control in a real-world population with type 2 diabetes mellitus in the United Arab Emirates: Results from the multicentre, prospective INTENSIFY study.
    Abusnana S; Al Awadi F; Aly H; Bashier A; Kumar Dhanwal D; Halasa T; Jallo M; Medina J; Singhal S
    Diabetes Res Clin Pract; 2023 Feb; 196():110183. PubMed ID: 36436550
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evaluation of Outcomes After Initiating Triple Antidiabetic Therapy with a GLP-1 RA in an Integrated Health Care System.
    Lee SM; Aboubechara N; Niu F; Ledesma VM; Patel YA; Millares M; Hui RL
    J Manag Care Spec Pharm; 2019 Mar; 25(3):350-356. PubMed ID: 30816819
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The real-world observational prospective study of health outcomes with dulaglutide and liraglutide in type 2 diabetes patients (TROPHIES): resource use and costs of treatment in clinical practice in France, Germany, and Italy.
    Barrett A; Boye KS; García-Pérez LE; Giorgino F; Guerci B; Füchtenbusch M; Yu M; Sapin H; Dib A; Heitmann E; Federici MO; Lebrec J
    J Med Econ; 2024; 27(1):866-879. PubMed ID: 38963346
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Real-world persistence, adherence, health care resource utilization, and costs in people with type 2 diabetes switching from a first-generation basal insulin to a second-generation (insulin glargine 300 U/mL) vs an alternative first-generation basal insulin.
    Wright EE; Malone DC; Trujillo JM; Gill J; Huse S; Li X; Zhou FL; Preblick R; Reid T
    J Manag Care Spec Pharm; 2022 Jun; 28(6):592-603. PubMed ID: 35352995
    [No Abstract]   [Full Text] [Related]  

  • 52. Clinical inertia in patients with type 2 diabetes treated with oral antidiabetic drugs: Results from a Japanese cohort study (JDDM53).
    Maegawa H; Ishigaki Y; Langer J; Saotome-Nakamura A; Andersen M;
    J Diabetes Investig; 2021 Mar; 12(3):374-381. PubMed ID: 32643314
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people.
    Khunti K; Wolden ML; Thorsted BL; Andersen M; Davies MJ
    Diabetes Care; 2013 Nov; 36(11):3411-7. PubMed ID: 23877982
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Benefits of combination of insulin degludec and liraglutide are independent of baseline glycated haemoglobin level and duration of type 2 diabetes.
    Rodbard HW; Buse JB; Woo V; Vilsbøll T; Langbakke IH; Kvist K; Gough SC
    Diabetes Obes Metab; 2016 Jan; 18(1):40-8. PubMed ID: 26343931
    [TBL] [Abstract][Full Text] [Related]  

  • 55. GLP1-RA Add-on Therapy in Patients with Type 2 Diabetes Currently on a Bolus Containing Insulin Regimen.
    Davies ML; Pham DQ; Drab SR
    Pharmacotherapy; 2016 Aug; 36(8):893-905. PubMed ID: 27340935
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Glucagon-Like Peptide 1 Receptor Agonists in Type 2 Diabetes Mellitus: Data from a Real-World Study in Spain.
    Norrbacka K; Sicras-Mainar A; Lebrec J; Artime E; Díaz S; Tofé-Povedano S; Hernández I; Romera I
    Diabetes Ther; 2021 May; 12(5):1535-1551. PubMed ID: 33860927
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Intensification of Basal Insulin Therapy with Lixisenatide in Patients with Type 2 Diabetes in a Real-World Setting: The BASAL-LIXI Study.
    Bellido D; Abellán P; Ruiz Palomar JM; Álvarez Sintes R; Nubiolae A; Bellido V; Romero G;
    Curr Ther Res Clin Exp; 2018; 89():37-42. PubMed ID: 30455779
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A Systematic Literature Review and Network Meta-Analysis Comparing Once-Weekly Semaglutide with Other GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Previously Receiving Basal Insulin.
    Witkowski M; Wilkinson L; Webb N; Weids A; Glah D; Vrazic H
    Diabetes Ther; 2018 Jun; 9(3):1233-1251. PubMed ID: 29713961
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evaluation of Out-of-Pocket Costs and Treatment Intensification With an SGLT2 Inhibitor or GLP-1 RA in Patients With Type 2 Diabetes and Cardiovascular Disease.
    Luo J; Feldman R; Callaway Kim K; Rothenberger S; Korytkowski M; Hernandez I; Gellad WF
    JAMA Netw Open; 2023 Jun; 6(6):e2317886. PubMed ID: 37307000
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Outcomes in GLP-1 RA-Experienced Patients Switching to Once-Weekly Semaglutide in a Real-World Setting: The Retrospective, Observational EXPERT Study.
    Lingvay I; Kirk AR; Lophaven S; Wolden ML; Shubrook JH
    Diabetes Ther; 2021 Mar; 12(3):879-896. PubMed ID: 33594582
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.